MedicaidPrior AuthMedium impact
Cyramza (ramucirumab) (New)
Humana·OH · Oncology, Hematology·Medicaid
Effective date
Mar 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicaid Ohio has established a new prior authorization policy for Cyramza (ramucirumab) covering six cancer indications including esophageal, colorectal, lung, and gastric cancers. The policy requires specific criteria to be met for each indication and excludes members who have experienced disease progression while on Cyramza.
Action Required
Before March 1, 2026: Billing and clinical teams must implement prior authorization requirements for Cyramza (ramucirumab) for Humana Medicaid Ohio members. Update authorization workflows to verify patient diagnosis, prior therapy history, and combination therapy requirements for each of the six covered cancer indications. Ensure documentation includes specific biomarker testing results where required (EGFR mutations for lung cancer, alpha fetoprotein levels for hepatocellular carcinoma). Claims will be denied without proper prior authorization.